| Year |
Citation |
Score |
| 2019 |
Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. Plos One. 14: e0215409. PMID 31026288 DOI: 10.1371/journal.pone.0215409 |
0.6 |
|
| 2019 |
Yamamoto KN, Liu LL, Nakamura A, Haeno H, Michor F. Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion. Jco Clinical Cancer Informatics. 1-11. PMID 30901235 DOI: 10.1200/CCI.18.00079 |
0.6 |
|
| 2018 |
Stein S, Zhao R, Haeno H, Vivanco I, Michor F. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. Plos Computational Biology. 14: e1005924. PMID 29293494 DOI: 10.1371/journal.pcbi.1005924 |
0.6 |
|
| 2017 |
Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass A, ... ... Michor F, et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nature Biotechnology. PMID 28892075 DOI: 10.1038/nbt.3966 |
0.48 |
|
| 2016 |
Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, Meric-Bernstam F, Michor F, Navin NE. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nature Genetics. PMID 27526321 DOI: 10.1038/ng.3641 |
1 |
|
| 2016 |
Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, Holland EC. ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Scientific Reports. 6: 25956. PMID 27456282 DOI: 10.1038/srep25956 |
1 |
|
| 2016 |
Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades CS, Viselli S, Neuwirth R, Esseltine DL, Anderson KC, Ghobrial IM, San Miguel J, Richardson PG, Tomasson MH, Michor F. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27006493 DOI: 10.1158/1078-0432.CCR-15-2793 |
1 |
|
| 2015 |
Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nature Reviews. Cancer. 15: 730-45. PMID 26597528 DOI: 10.1038/nrc4029 |
1 |
|
| 2015 |
Michor F, Beal K. Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell. 163: 1059-1063. PMID 26590416 DOI: 10.1016/j.cell.2015.11.002 |
1 |
|
| 2015 |
Liu LL, Li F, Pao W, Michor F. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. Plos One. 10: e0141665. PMID 26536620 DOI: 10.1371/journal.pone.0141665 |
1 |
|
| 2015 |
Foo J, Liu LL, Leder K, Riester M, Iwasa Y, Lengauer C, Michor F. An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. Plos Computational Biology. 11: e1004350. PMID 26379039 DOI: 10.1371/journal.pcbi.1004350 |
1 |
|
| 2015 |
Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics. 14: 19-31. PMID 26244007 DOI: 10.4137/CIN.S19338 |
1 |
|
| 2015 |
Badri H, Pitter K, Holland EC, Michor F, Leder K. Optimization of radiation dosing schedules for proneural glioblastoma. Journal of Mathematical Biology. PMID 26094055 DOI: 10.1007/s00285-015-0908-x |
1 |
|
| 2015 |
Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. Bmc Cancer. 15: 242. PMID 25886454 DOI: 10.1186/s12885-015-1192-2 |
1 |
|
| 2015 |
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, ... ... Michor F, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine. 21: 440-8. PMID 25849130 DOI: 10.1038/nm.3841 |
1 |
|
| 2015 |
Selmecki AM, Maruvka YE, Richmond PA, Guillet M, Shoresh N, Sorenson AL, De S, Kishony R, Michor F, Dowell R, Pellman D. Polyploidy can drive rapid adaptation in yeast. Nature. 519: 349-52. PMID 25731168 DOI: 10.1038/nature14187 |
1 |
|
| 2015 |
Ashcroft P, Michor F, Galla T. Stochastic tunneling and metastable states during the somatic evolution of cancer. Genetics. 199: 1213-28. PMID 25624316 DOI: 10.1534/genetics.114.171553 |
1 |
|
| 2015 |
Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, ... ... Michor F, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discovery. 5: 316-31. PMID 25572172 DOI: 10.1158/2159-8290.CD-14-0736 |
1 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer Nature Genetics. DOI: 10.1038/ng.3391 |
1 |
|
| 2015 |
Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, ... ... Michor F, et al. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation Cell Reports. DOI: 10.1016/j.celrep.2015.06.059 |
1 |
|
| 2014 |
Shaknovich R, De S, Michor F. Epigenetic diversity in hematopoietic neoplasms. Biochimica Et Biophysica Acta. 1846: 477-84. PMID 25240947 DOI: 10.1016/j.bbcan.2014.09.003 |
1 |
|
| 2014 |
Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 99: 1701-9. PMID 25216683 DOI: 10.3324/haematol.2013.085977 |
1 |
|
| 2014 |
Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 26: 288-300. PMID 25117714 DOI: 10.1016/j.ccr.2014.06.005 |
1 |
|
| 2014 |
Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 514: 54-8. PMID 25079331 DOI: 10.1038/nature13556 |
1 |
|
| 2014 |
Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 512: 155-60. PMID 25079324 DOI: 10.1038/nature13600 |
1 |
|
| 2014 |
Maruvka YE, Tang M, Michor F. On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. Plos One. 9: e83100. PMID 25054541 DOI: 10.1371/journal.pone.0083100 |
1 |
|
| 2014 |
Podlaha O, De S, Gonen M, Michor F. Histone modifications are associated with transcript isoform diversity in normal and cancer cells. Plos Computational Biology. 10: e1003611. PMID 24901363 DOI: 10.1371/journal.pcbi.1003611 |
1 |
|
| 2014 |
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, ... ... Michor F, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine. 3: 835-44. PMID 24846059 DOI: 10.1002/cam4.262 |
1 |
|
| 2014 |
Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute. 106. PMID 24700803 DOI: 10.1093/jnci/dju048 |
1 |
|
| 2014 |
Michor F, Weaver VM. Understanding tissue context influences on intratumour heterogeneity. Nature Cell Biology. 16: 301-2. PMID 24691256 DOI: 10.1038/ncb2942 |
1 |
|
| 2014 |
Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. Journal of Theoretical Biology. 355: 10-20. PMID 24681298 DOI: 10.1016/j.jtbi.2014.02.025 |
1 |
|
| 2014 |
Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, ... ... Michor F, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1873-83. PMID 24486590 DOI: 10.1158/1078-0432.CCR-13-0759 |
1 |
|
| 2014 |
Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 156: 603-16. PMID 24485463 DOI: 10.1016/j.cell.2013.12.029 |
1 |
|
| 2014 |
Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, ... ... Michor F, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Reports. 6: 514-27. PMID 24462293 DOI: 10.1016/j.celrep.2013.12.041 |
1 |
|
| 2014 |
Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K. Genetic and phenotypic diversity in breast tumor metastases. Cancer Research. 74: 1338-48. PMID 24448237 DOI: 10.1158/0008-5472.CAN-13-2357-T |
1 |
|
| 2014 |
Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 123: 1699-708. PMID 24385541 DOI: 10.1182/blood-2013-07-509885 |
1 |
|
| 2014 |
Randles A, Draeger E, Michor F. Analysis of pressure gradient across aortic stenosis with massively parallel computational simulations Computing in Cardiology. 41: 217-220. |
1 |
|
| 2013 |
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology. 163: 674-6. PMID 24032404 DOI: 10.1111/bjh.12532 |
1 |
|
| 2013 |
Haeno H, Maruvka YE, Iwasa Y, Michor F. Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. Plos One. 8: e65724. PMID 23840359 DOI: 10.1371/journal.pone.0065724 |
1 |
|
| 2013 |
Zhao R, Michor F. Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. Plos Computational Biology. 9: e1003082. PMID 23785264 DOI: 10.1371/journal.pcbi.1003082 |
1 |
|
| 2013 |
Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, ... ... Michor F, et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 13: 117-30. PMID 23770079 DOI: 10.1016/j.stem.2013.05.004 |
1 |
|
| 2013 |
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/gr.152322.112 |
1 |
|
| 2013 |
Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, ... ... Michor F, et al. A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports. 3: 1449. PMID 23618955 DOI: 10.1038/srep01449 |
1 |
|
| 2013 |
Liu L, De S, Michor F. DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nature Communications. 4: 1502. PMID 23422670 DOI: 10.1038/ncomms2502 |
1 |
|
| 2013 |
Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1070-80. PMID 23401451 DOI: 10.1200/JCO.2012.43.3912 |
1 |
|
| 2013 |
De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. Plos Genetics. 9: e1003137. PMID 23326238 DOI: 10.1371/journal.pgen.1003137 |
1 |
|
| 2012 |
Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/JTO.0b013e31826146ee |
1 |
|
| 2012 |
Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discovery. 2: 503-11. PMID 22628410 DOI: 10.1158/2159-8290.CD-11-0325 |
1 |
|
| 2012 |
Tang M, Foo J, Gönen M, Guilhot J, Mahon FX, Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 97: 1553-61. PMID 22419579 DOI: 10.3324/haematol.2012.062844 |
1 |
|
| 2012 |
Iwami S, Haeno H, Michor F. A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. Plos Computational Biology. 8: e1002370. PMID 22359489 DOI: 10.1371/journal.pcbi.1002370 |
1 |
|
| 2012 |
Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends in Genetics : Tig. 28: 155-63. PMID 22342180 DOI: 10.1016/j.tig.2012.01.003 |
1 |
|
| 2012 |
Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 148: 362-75. PMID 22265421 DOI: 10.1016/j.cell.2011.11.060 |
1 |
|
| 2012 |
Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Holland EC, Michor F. A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. Plos Computational Biology. 8: e1002337. PMID 22241976 DOI: 10.1371/journal.pcbi.1002337 |
1 |
|
| 2012 |
Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1323-33. PMID 22228636 DOI: 10.1158/1078-0432.CCR-11-2271 |
1 |
|
| 2012 |
Agus DB, Michor F. The sciences converge to fight cancer Nature Physics. 8: 773-774. DOI: 10.1038/nphys2464 |
1 |
|
| 2012 |
De S, Michor F. De and Michor respond Nature Biotechnology. 30: 1045-1046. DOI: 10.1038/nbt.2414 |
1 |
|
| 2011 |
Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. Plos One. 6: e27682. PMID 22140458 DOI: 10.1371/journal.pone.0027682 |
1 |
|
| 2011 |
De S, Michor F. DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nature Biotechnology. 29: 1103-8. PMID 22101487 DOI: 10.1038/nbt.2030 |
1 |
|
| 2011 |
Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Pharmaceutics. 8: 2069-79. PMID 21995722 DOI: 10.1021/mp200270v |
1 |
|
| 2011 |
Hambardzumyan D, Cheng YK, Haeno H, Holland EC, Michor F. The probable cell of origin of NF1- and PDGF-driven glioblastomas. Plos One. 6: e24454. PMID 21931722 DOI: 10.1371/journal.pone.0024454 |
1 |
|
| 2011 |
Michor F, Liphardt J, Ferrari M, Widom J. What does physics have to do with cancer? Nature Reviews. Cancer. 11: 657-70. PMID 21850037 DOI: 10.1038/nrc3092 |
1 |
|
| 2011 |
Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, ... ... Michor F, et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 118: 3559-69. PMID 21828137 DOI: 10.1182/blood-2011-06-357996 |
1 |
|
| 2011 |
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, ... ... Michor F, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/scitranslmed.3002356 |
1 |
|
| 2011 |
De S, Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nature Structural & Molecular Biology. 18: 950-5. PMID 21725294 DOI: 10.1038/nsmb.2089 |
1 |
|
| 2011 |
Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 118: 1622-31. PMID 21653938 DOI: 10.1182/blood-2011-02-339267 |
1 |
|
| 2011 |
Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, ... ... Michor F, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 473: 230-3. PMID 21562564 DOI: 10.1038/nature09999 |
1 |
|
| 2011 |
Iwasa Y, Michor F. Evolutionary dynamics of intratumor heterogeneity. Plos One. 6: e17866. PMID 21479218 DOI: 10.1371/journal.pone.0017866 |
1 |
|
| 2011 |
Durrett R, Foo J, Leder K, Mayberry J, Michor F. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 188: 461-77. PMID 21406679 DOI: 10.1534/genetics.110.125724 |
1 |
|
| 2011 |
Foo J, Leder K, Michor F. Stochastic dynamics of cancer initiation. Physical Biology. 8: 015002. PMID 21301064 DOI: 10.1088/1478-3975/8/1/015002 |
1 |
|
| 2011 |
De Vargas Roditi L, Michor F. Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. Journal of Theoretical Biology. 273: 207-15. PMID 21194536 DOI: 10.1016/j.jtbi.2010.12.033 |
1 |
|
| 2011 |
Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Michor F. Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation Proceedings of the National Academy of Sciences of the United States of America. 108: E16. DOI: 10.1073/pnas.1018584108 |
1 |
|
| 2010 |
Leder K, Holland EC, Michor F. The therapeutic implications of plasticity of the cancer stem cell phenotype. Plos One. 5: e14366. PMID 21179426 DOI: 10.1371/journal.pone.0014366 |
1 |
|
| 2010 |
Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prevention Research (Philadelphia, Pa.). 3: 1361-4. PMID 20959519 DOI: 10.1158/1940-6207.CAPR-10-0234 |
1 |
|
| 2010 |
Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 107: 17604-9. PMID 20864632 DOI: 10.1073/pnas.1009117107 |
1 |
|
| 2010 |
Danielson LS, Menendez S, Attolini CS, Guijarro MV, Bisogna M, Wei J, Socci ND, Levine DA, Michor F, Hernando E. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. The American Journal of Pathology. 177: 908-17. PMID 20558575 DOI: 10.2353/ajpath.2010.091150 |
1 |
|
| 2010 |
Durrett R, Foo J, Leder K, Mayberry J, Michor F. Evolutionary dynamics of tumor progression with random fitness values. Theoretical Population Biology. 78: 54-66. PMID 20488197 DOI: 10.1016/j.tpb.2010.05.001 |
1 |
|
| 2010 |
Riester M, Stephan-Otto Attolini C, Downey RJ, Singer S, Michor F. A differentiation-based phylogeny of cancer subtypes. Plos Computational Biology. 6: e1000777. PMID 20463876 DOI: 10.1371/journal.pcbi.1000777 |
1 |
|
| 2010 |
Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. The Journal of Clinical Investigation. 120: 636-44. PMID 20101094 DOI: 10.1172/JCI40724 |
1 |
|
| 2010 |
Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. Journal of Theoretical Biology. 263: 179-88. PMID 20004211 DOI: 10.1016/j.jtbi.2009.11.022 |
1 |
|
| 2010 |
Haeno H, Michor F. The evolution of tumor metastases during clonal expansion. Journal of Theoretical Biology. 263: 30-44. PMID 19917298 DOI: 10.1016/j.jtbi.2009.11.005 |
1 |
|
| 2009 |
Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. Plos Computational Biology. 5: e1000557. PMID 19893626 DOI: 10.1371/journal.pcbi.1000557 |
1 |
|
| 2009 |
Haeno H, Levine RL, Gilliland DG, Michor F. A progenitor cell origin of myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America. 106: 16616-21. PMID 19805346 DOI: 10.1073/pnas.0908107106 |
1 |
|
| 2009 |
Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. Plos Computational Biology. 5: e1000503. PMID 19749982 DOI: 10.1371/journal.pcbi.1000503 |
1 |
|
| 2009 |
Attolini CS, Michor F. Evolutionary theory of cancer. Annals of the New York Academy of Sciences. 1168: 23-51. PMID 19566702 DOI: 10.1111/j.1749-6632.2009.04880.x |
1 |
|
| 2008 |
Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S, Thiede C, Schnittger S, Valk PJ, Döhner K, Martelli MF, Schaich M, Krauter J, Ganser A, Martelli MP, ... ... Michor F, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 93: 1219-26. PMID 18603563 DOI: 10.3324/haematol.13209 |
1 |
|
| 2008 |
Michor F. Mathematical models of cancer stem cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2854-61. PMID 18539964 DOI: 10.1200/JCO.2007.15.2421 |
1 |
|
| 2007 |
Haeno H, Iwasa Y, Michor F. The evolution of two mutations during clonal expansion. Genetics. 177: 2209-21. PMID 18073428 DOI: 10.1534/genetics.107.078915 |
1 |
|
| 2007 |
Michor F. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends in Pharmacological Sciences. 28: 197-9. PMID 17412430 DOI: 10.1016/j.tips.2007.03.003 |
1 |
|
| 2007 |
Dingli D, Michor F, Antal T, Pacheco JM. The emergence of tumor metastases. Cancer Biology & Therapy. 6: 383-90. PMID 17312385 |
1 |
|
| 2007 |
Michor F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells (Dayton, Ohio). 25: 1114-8. PMID 17218393 DOI: 10.1634/stemcells.2006-0638 |
1 |
|
| 2007 |
Dingli D, Traulsen A, Michor F. Correction: (A)Symmetric Stem Cell Replication and Cancer Plos Computational Biology. 3: e83. DOI: 10.1371/JOURNAL.PCBI.0030083 |
0.44 |
|
| 2007 |
Michor F. Reply: The long-term response to imatinib treatment of CML [2] British Journal of Cancer. 96: 679-680. DOI: 10.1038/sj.bjc.6603604 |
1 |
|
| 2006 |
Michor F, Iwasa Y, Nowak MA. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proceedings of the National Academy of Sciences of the United States of America. 103: 14931-4. PMID 17001000 DOI: 10.1073/pnas.0607006103 |
1 |
|
| 2006 |
Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells (Dayton, Ohio). 24: 2603-10. PMID 16931775 DOI: 10.1634/stemcells.2006-0136 |
1 |
|
| 2006 |
Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics. 172: 2557-66. PMID 16636113 DOI: 10.1534/genetics.105.049791 |
1 |
|
| 2006 |
Michor F, Iwasa Y. Dynamics of metastasis suppressor gene inactivation. Journal of Theoretical Biology. 241: 676-89. PMID 16497335 DOI: 10.1016/j.jtbi.2006.01.006 |
1 |
|
| 2006 |
Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Current Pharmaceutical Design. 12: 261-71. PMID 16454743 DOI: 10.2174/138161206775201956 |
1 |
|
| 2006 |
Nowak MA, Michor F, Iwasa Y. Genetic instability and clonal expansion. Journal of Theoretical Biology. 241: 26-32. PMID 16405914 DOI: 10.1016/j.jtbi.2005.11.012 |
1 |
|
| 2006 |
Brumer Y, Michor F, Shakhnovich EI. Genetic instability and the quasispecies model. Journal of Theoretical Biology. 241: 216-22. PMID 16386760 DOI: 10.1016/j.jtbi.2005.11.018 |
1 |
|
| 2006 |
Michor F, Nowak MA, Iwasa Y. Stochastic dynamics of metastasis formation. Journal of Theoretical Biology. 240: 521-30. PMID 16343545 DOI: 10.1016/j.jtbi.2005.10.021 |
1 |
|
| 2006 |
Hauert C, Michor F, Nowak MA, Doebeli M. Synergy and discounting of cooperation in social dilemmas. Journal of Theoretical Biology. 239: 195-202. PMID 16242728 DOI: 10.1016/j.jtbi.2005.08.040 |
1 |
|
| 2005 |
Michor F, Iwasa Y, Lengauer C, Nowak MA. Dynamics of colorectal cancer. Seminars in Cancer Biology. 15: 484-93. PMID 16055342 DOI: 10.1016/j.semcancer.2005.06.005 |
1 |
|
| 2005 |
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/nature03669 |
1 |
|
| 2005 |
Michor F. Chromosomal instability and human cancer. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 360: 631-5. PMID 15897185 DOI: 10.1098/rstb.2004.1617 |
1 |
|
| 2005 |
Iwasa Y, Michor F, Komarova NL, Nowak MA. Population genetics of tumor suppressor genes. Journal of Theoretical Biology. 233: 15-23. PMID 15615616 DOI: 10.1016/j.jtbi.2004.09.001 |
1 |
|
| 2005 |
Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Seminars in Cancer Biology. 15: 43-9. PMID 15613287 DOI: 10.1016/j.semcancer.2004.09.007 |
1 |
|
| 2005 |
Iwasa Y, Michor F, Nowak MA. Virus evolution within patients increases pathogenicity. Journal of Theoretical Biology. 232: 17-26. PMID 15498589 DOI: 10.1016/j.jtbi.2004.07.016 |
1 |
|
| 2004 |
Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. The Journal of Experimental Medicine. 200: 1243-56. PMID 15545352 DOI: 10.1084/jem.20040511 |
1 |
|
| 2004 |
Nowak MA, Michor F, Komarova NL, Iwasa Y. Evolutionary dynamics of tumor suppressor gene inactivation. Proceedings of the National Academy of Sciences of the United States of America. 101: 10635-8. PMID 15252197 DOI: 10.1073/pnas.0400747101 |
1 |
|
| 2004 |
Iwasa Y, Michor F, Nowak M. Some basic properties of immune selection. Journal of Theoretical Biology. 229: 179-88. PMID 15207473 DOI: 10.1016/j.jtbi.2004.03.013 |
1 |
|
| 2004 |
Iwasa Y, Michor F, Nowak MA. Stochastic tunnels in evolutionary dynamics. Genetics. 166: 1571-9. PMID 15082570 DOI: 10.1534/genetics.166.3.1571 |
1 |
|
| 2004 |
Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nature Reviews. Cancer. 4: 197-205. PMID 14993901 DOI: 10.1038/nrc1295 |
1 |
|
| 2004 |
Michor F, Iwasa Y, Rajagopalan H, Lengauer C, Nowak MA. Linear model of colon cancer initiation. Cell Cycle (Georgetown, Tex.). 3: 358-62. PMID 14726709 |
1 |
|
| 2004 |
Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of invasion and escape. Journal of Theoretical Biology. 226: 205-14. PMID 14643190 DOI: 10.1016/j.jtbi.2003.08.014 |
1 |
|
| 2003 |
Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of escape from biomedical intervention. Proceedings. Biological Sciences / the Royal Society. 270: 2573-8. PMID 14728779 DOI: 10.1098/rspb.2003.2539 |
1 |
|
| 2003 |
Nowak MA, Michor F, Iwasa Y. The linear process of somatic evolution. Proceedings of the National Academy of Sciences of the United States of America. 100: 14966-9. PMID 14657359 DOI: 10.1073/pnas.2535419100 |
1 |
|
| 2003 |
Michor F, Frank SA, May RM, Iwasa Y, Nowak MA. Somatic selection for and against cancer. Journal of Theoretical Biology. 225: 377-82. PMID 14604590 DOI: 10.1016/S0022-5193(03)00267-4 |
1 |
|
| 2003 |
Michor F, Nowak MA, Frank SA, Iwasa Y. Stochastic elimination of cancer cells. Proceedings. Biological Sciences / the Royal Society. 270: 2017-24. PMID 14561289 DOI: 10.1098/rspb.2003.2483 |
1 |
|
| 2003 |
Michor F, Iwasa Y, Komarova NL, Nowak MA. Local regulation of homeostasis favors chromosomal instability. Current Biology : Cb. 13: 581-4. PMID 12676089 DOI: 10.1016/S0960-9822(03)00172-6 |
1 |
|
| 2002 |
Michor F, Nowak MA. Evolution: the good, the bad and the lonely. Nature. 419: 677, 679. PMID 12384681 DOI: 10.1038/419677a |
1 |
|
| Show low-probability matches. |